Search

Your search keyword '"Ortega-Castro R"' showing total 136 results

Search Constraints

Start Over You searched for: Author "Ortega-Castro R" Remove constraint Author: "Ortega-Castro R"
136 results on '"Ortega-Castro R"'

Search Results

1. AB0694 BARICITINIB IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 60 PATIENTS

2. POS0689 WINDOW OF OPPORTUNITY IN THE TREATMENT OF RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE WITH ABATACEPT. NATIONAL MULTICENTER STUDY OF 526 PATIENTS

3. POS0130 THE USE OF HIGH-THROUGHPUT TECHNOLOGIES FOR MOLECULAR PROFILING IN RHEUMATOID ARTHRITIS ENABLES THE IDENTIFICATION OF PATIENT SUBGROUPS WITH DISTINCTIVE DISEASE ACTIVITY AND THERAPEUTIC RESPONSE

4. POS0154 EARLY AND ESTABLISHED RHEUMATOID ARTHRITIS PATIENTS EXHIBIT DISTINCTIVE CIRCULATING INFLAMMATORY SIGNATURES ASSOCIATED WITH RELEVANT BIOLOGIC PATHWAYS

5. POS1401 INTEGRATION OF PROTEOMIC AND METABOLOMIC ANALYSES FOR STRATIFYING SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: UNVEILING SIGNATURES ASSOCIATED WITH CARDIOVASCULAR RISK AND RENAL COMPLICATIONS

6. POS0035 INFLUENCE OF INTERSTITIAL LUNG DISEASE DURATION ON THE TREATMENT OF RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 392 PATIENTS WITH ABATACEPT

8. POS0835 EFFECTIVENESS AND SAFETY OF JAK INHIBITORS IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 57 PATIENTS

9. POS0293 METABOLOMIC IN ANTIPHOSPHOLIPID SYNDROME STRATIFIED PATIENTS ACCORDING TO THEIR THROMBOTIC RISK

10. POS0623 INTEGRATED SERUM PROTEOMIC AND METABOLOMIC PROFILES IN SYSTEMIC SCLEROSIS PATIENTS CHARACTERIZE NEW BIOMARKERS ASSOCIATED TO RELEVANT PATHOLOGICAL FEATURES

11. AB0416 SUBCUTANEUS VS INTRAVENOUS ABATACEPT IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 392 PATIENTS

12. OP0126 LONG-TERM FOLLOW UP OF ABATACEPT IN USUAL INTERSTITIAL PNEUMONIA ASSOCIATED TO RHEUMATOID ARTHRITIS. NATIONAL MULTICENTER STUDY OF 172 PATIENTS

13. AB0334 PREVALENCE AND ASSOCIATED FACTORS OF MULTIMORBIDITY IN PATIENTS WITH STABLISHED RHEUMATOID ARTHRITIS. DATA FROM THE CRHREAR REGISTRY

14. OP0023 UNBIASED HIERARCHICAL CLUSTERING OF CIRCULATING MOLECULAR PROFILES IN RHEUMATOID ARTHRITIS PATIENTS DEFINES PRECISE CV RISK. EFFECTS OF TNFI, IL6RI, AND JAKINIBS

15. POS1041 LIPID METABOLISM IS DEEPLY ALTERED IN ACTIVE RHEUMATOID ARTHRITIS PATIENTS AND REVERSED BY ANTI-TNF, ANTI-IL6R, AND JAK-INHIBITORS

16. POS0350 PROXIMITY EXTENSION ASSAY AS A NOVEL TECHNOLOGY FOR BOOSTING MOLECULAR CHARACTERIZATION AND PERSONALIZED CLINICAL MANAGEMENT OF RHEUMATIC DISEASES

17. POS1142 SPANISH NATIONAL REGISTRY OF BELIMUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

18. POS1073 IMPACT OF COMORBIDITIES ON THE FIRST BDMARD EFFECTIVENESS AND RETENTION RATE AFTER 2 YEARS OF FOLLOW-UP IN PATIENTS WITH RHEUMATOID ARTHRITIS. DATA FROM THE SPANISH REGISTRY BIOBADASER

19. Splicing machinery is profoundly altered in systemic lupus erythematosus and antiphospholipid syndrome and directly linked to key clinical features

20. POS0058 IDENTIFICATION OF NOVEL BIOMARKERS OF DISEASE ACTIVITY IN SYSTEMIC AUTOIMMUNE DISEASES THROUGH NEXT GENERATION PROTEOMICS

21. AB1149 EVALUATION OF THE EFFICACY AND SAFETY OF THE SARS-CoV-2 VACCINE IN PATIENTS WITH CHRONIC INFLAMMATORY DISEASES TREATED WITH BIOLOGICAL THERAPY.

22. POS0907 ASSOCIATION BETWEEN DISEASE ACTIVITY AND DAMAGE IN IDIOPATHIC INFLAMMATORY MYOPATHIES. DIFFERENCES BETWEEN INCIDENT AND PREVALENT CASES

24. POS0465 UNSUPERVISED CLUSTERING ANALYSIS OF THE SERUM PROTEOME IDENTIFIES SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH DISTINCTIVE DISEASE SEVERITY AND LUPUS NEPHROPATHY

25. POS0327 IRISIN: A NEW MARKER OF SUBCLINICAL ATHEROSCLEROSIS, CARDIOVASCULAR RISK AND DISEASE ACTIVITY IN AXIAL SPONDYLOARTHRITIS?

26. AB0084 INCREASED LIVER DISEASE RISK IN RHEUMATOID ARTHRITIS IS ASSOCIATED WITH DISEASE ACTIVITY, INFLAMMATORY MARKERS, INSULIN RESISTANCE AND ACPAs. INFLUENCE OF METHOTREXATE

27. POS0440 THE ANALYSIS OF THE INFLAMMATORY PROTEOME IN RHEUMATOID ARTHRITIS IDENTIFIES COMMON SIGNATURES ASSOCIATED WITH THE CLINICAL RESPONSE TO DMARDs AND TNFi THERAPIES

28. OP0231 MASS CYTOMETRY DATA RECLASSIFY SYSTEMIC AUTOIMMUNE DISEASE PATIENTS IN PHENOTYPICALLY DISTINCTIVE GROUPS

30. POS0488 IDENTIFICATION OF NOVEL DISEASE BIOMARKERS IN SYSTEMIC SCLEROSIS THROUGH HIGH-THROUGHPUT PROTEOMICS

31. Impact of rheumatoid arthritis on sexuality: adaptation and validation of the Qualisex questionnaire for use in Spain

32. POS0211 PREDICTORS OF PROGRESSION AND MORTALITY IN PATIENTS WITH PREVALENT RHEUMATOID ARTHRITIS AND INTERSTITIAL LUNG DISEASE: A PROSPECTIVE COHORT STUDY

35. POS0475 INTEGRATIVE CLINICAL, MOLECULAR AND COMPUTATIONAL ANALYSES ALLOW THE IDENTIFICATION OF DISTINCTIVE PHENOTYPES OF RHEUMATOID ARTHRITIS PATIENTS RELATED TO THE CLINICAL INVOLVEMENT AND THE RESPONSE TO TNF INHIBITORS

37. AB0070 ROLE OF VASPIN IN ATHEROSCLEROTIC DISEASE AND CARDIOVASCULAR RISK IN AXIAL SPONDYLOARTHRITIS

39. INFLUENCE OF INTERSTITIAL LUNG DISEASE DURATION ON THE TREATMENT OF RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 392 PATIENTS WITH ABATACEPT.

40. Genome-wide whole blood transcriptome profiling in a large European cohort of systemic sclerosis patients

41. SAT0043 SERUM BIOMOLECULES AS POTENTIAL BIOMARKERS OF CLINICAL EFFICACY AND PREDICTORS OF RESPONSE TO BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS PATIENTS

42. AB0338 EVALUATION OF THE ASSOCIATION OF ALLELES OF INTOLERANCE RISK TO METOTREXATE IN RHEUMATOID ARTHRITIS PATIENTS UNDER TREATMENT WITH BIOLOGIC THERAPIES

43. FRI0316 CAN THE MOMENT OF OCCURRENCE OF THE FIRST EPISODE OF UVEITIS PREDICT DIFFERENCES IN THE PROGNOSIS OF SPONDYLOARTHRITIS? DATA FROM THE SPANISH REGISTRY REGISPONSER

44. SAT0373 QUANTITATIVE ASSESSMENT OF RESPONSIVENESS IN SACROILIAC JOINTS MRI OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A PILOT STUDY.

45. AB0136 THE SUSTAINED POSITIVITY FOR ANTI-DSDNA ANTIBODIES FOSTERS THE ESTABLISHMENT OF AN ATHEROTHROMBOTIC STATUS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

47. SAT0529 CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS IN A PATIENT GROUP WITH INTERSTITIAL LUNG DISEASE.

48. OP0137 GENOME-WIDE WHOLE-BLOOD TRANSCRIPTOME PROFILING IN A LARGE EUROPEAN COHORT OF SYSTEMIC SCLEROSIS PATIENTS

49. FRI0321 UTILITY OF THE ASAS HEALTH INDEX QUESTIONNAIRE AS A TOOL FOR HEALTH ASSESSMENT IN PATIENTS WITH SPONDYLOARTHRITIS AND ITS ASSOCIATION WITH DISEASE ACTIVITY, FUNCTIONALITY, MOBILITY, AND STRUCTURAL DAMAGE

50. SAT0262 3-year follow-up of a dose tapering protocol of anti-tnf therapy in a cohort of patients with spondyloarthritis (SPA) in clinical remission under conditions of clinical practice

Catalog

Books, media, physical & digital resources